By Jasmine Li
Astellas Pharma's drug Vyloy was approved for treatment of advanced gastric and gastroesophageal junction cancer by the Food and Drug Administration.
The pharmaceutical company said Friday the FDA approved the drug for use in combination with fluoropyrimidine-and-platinum-containing chemotherapy. Vyloy is intended for the first-line treatment of patients whose tumors are claudin $(CLDN.UK)$ 18.2 positive, Astellas said.
The approval was based on results from Phase 3 clinical trials, and makes Vyloy the first and only CLDN18.2-targeted therapy approved in the U.S., the company said.
An FDA-approved test developed by Roche Holdings is used to identify patients who may be eligible for Vyloy, Astellas said. Vyloy was also approved in Japan, the U.K., the E.U. and South Korea this year.
Write to Jasmine Li at jasmine.li@wsj.com
(MORE TO FOLLOW) Dow Jones Newswires
October 18, 2024 15:29 ET (19:29 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。